Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | DNM2 | P50570 | 7/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12605112 | 0.82 | HRH3 (0.54) | HRH3TLR8DNM2HRH4CYP2C19 | |
| SCHEMBL3209288 | 0.78 | CYP2D6 (0.64) | HRH3TLR8DNM2HRH4CYP2C19 | |
| SCHEMBL17300725 | 0.75 | DNM2 (0.57) | HRH3DNM2HRH4CYP2C19 | |
| SCHEMBL2166206 | 0.72 | HRH3 (0.53) | HRH3HSD17B10HRH4 | |
| SCHEMBL17985629 | 0.71 | TLR8 (0.69) | HRH3HSD17B10TLR8DNM2HRH4 | |
| SCHEMBL2567744 | 0.71 | DNM2 (0.64) | HRH3DNM2HRH4CYP2D6 | |
| SCHEMBL16840340 | 0.70 | HRH3 (1.00) | HRH3TLR8DNM2HRH4CYP2C19 | |
| SCHEMBL11447017 | 0.70 | NOS1 (0.52) | HRH3DNM2CYP2C19NCF1 | |
| SCHEMBL18007575 | 0.70 | HSD17B10 (0.72) | HSD17B10HRH4 | |
| SCHEMBL2166250 | 0.70 | HSD17B10 (0.45) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008060766-A2 | HISTAMINE H4 RECEPTOR LIGANDS FOR USE IN PAIN TREATMENT | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | HRH3 2/4885HSD17B10 3225/4885TLR8 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.